Life Sciences Tools and Services
Company Overview of Aegis Therapeutics, LLC
Aegis Therapeutics, LLC, a drug-delivery and drug-formulation technologies company, commercializes drug delivery and protein stabilization technologies to pharmaceutical and biopharmaceutical companies. It offers Intravail, a drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide, and non-peptide drugs. The company also provides ProTek to create homogeneous, stable, aqueous or lyophilized dosage forms for peptide or protein therapeutics. In addition, it offers Hydrogels, an absorption-enhancing self-assembling aqueous hydrogels for transdermal drug delivery or transmucosal application. The company was founded in 2003 and is based in San Diego, Ca...
11770 Bernardo Plaza Court
San Diego, CA 92128
Founded in 2003
Key Executives for Aegis Therapeutics, LLC
Chief Executive Officer and Director
Chief Business Officer and Director
Compensation as of Fiscal Year 2015.
Aegis Therapeutics, LLC Key Developments
Dauntless Pharmaceuticals Announces Licensing Agreement with Aegis Therapeutics
Jul 23 15
Dauntless Pharmaceuticals Inc. and Aegis Therapeutics, LLC have announced a licensing agreement providing Dauntless access to Aegis' Intravail (R) drug delivery technology for an undisclosed oncology application and an option for three additional drugs. Both the companies based in the US.
Aegis Offers Exclusive License to Develop, Commercialize, and Sell its Patented Non-Invasive Exenatide Metered Nasal Spray Diabetes Drug
Aug 5 14
Aegis announced that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug. Exenatide is a 39-amino acid synthetic peptide GLP-1 analog highly effective in controlling blood glucose levels in Type-2 diabetes. All currently available GLP-1 analogs require injection. The currently marketed injectable form of exenatide, sold under the trademark Byetta(R), requires twice daily injections. The Aegis patented Intravail(R) based formulation of exenatide provides equivalent blood levels using a simple metered nasal spray to replace each of the two daily injections. The total market for GLP-1 analogs is expected to grow to $5 billion within the next few years. As the only non-injectable option for patients seeking to avoid needles, needlestick injuries, and syringe disposal problems, the non-injectable Aegis nasal spray exenatide formulation is poised to achieve significant market share.
Aegis Therapeutics, LLC Presents at BIO International Convention, Jun-25-2014 04:15 PM
Jun 17 14
Aegis Therapeutics, LLC Presents at BIO International Convention, Jun-25-2014 04:15 PM. Venue: San Diego Convention Center, San Diego, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|